The primary pharmacological treatment of TD involves inhibitors of the vesicular monoamine transporter 2 (VMAT2), such as valbenazine and deutetrabenazine, which decrease TD symptoms by modulating dopamine release.2 This evidence concerns the gene SLC18A2 and thanatophoric dysplasia.